Dr. John Lewis is the co-founder of Oisin Oncology and heads its cancer-fighting platform technology development and clinical research. Dr. Lewis also holds the Frank and Carla Sojonky Chair in Prostate Cancer Research at the University of Alberta. He is an Associate Professor in the Department of Oncology and chairs the Alberta Prostate Cancer Research Initiative. Dr. Lewis has also founded three Canadian biotechnology companies. Dr. John Lewis’s research interests lie in the areas of nanotechnology and imaging as they relate to the development of novel treatments for chronic diseases such as aging and cancer. Because no man dies of prostate cancer that stays in his prostate, the group is studying the spread, or metastasis, of cancer using advanced live imaging techniques. The group has used this approach to identify key drivers of metastatic cancer progression and is leveraging this information to develop novel nanoparticles to block the spread of prostate and other cancers. Dr. Lewis is also the founder of several startups focused on the areas of LNP production.
The opinions expressed in interviews or commentary in articles appearing on this site are those of the subject or subjects and do not necessarily reflect the views of LEAF/Lifespan.io, its directors, officers or employees.